Walmart Inc. (WMT)

Key Updates

WMT has advanced 2.03% since the 3 September report (from $107.52 to $109.69), extending the rebound from the post-earnings trough of $104.87 recorded on 1 September. The stock is now approximately 4.6% above that low, though it remains well below pre-earnings levels. Newsflow since the last update has shifted from earnings-reaction commentary toward strategic growth narratives: Walmart China's 20.7% quarterly sales growth, the scaling of the high-margin Walmart Connect advertising business, and the expansion into restaurant delivery (Dunkin', building on the Subway partnership) have supported sentiment. No new financial results have been released since the 20 August Q2 FY2027 report; the recent price action reflects market digestion of that print and subsequent strategic announcements rather than new fundamental data.

Current Trend

WMT is down 1.54% YTD but has fallen 13.30% over six months, indicating that the stock traded meaningfully higher earlier in the year (implied ~$126.5 level six months ago) before a sharp correction, primarily triggered by the 20 August earnings miss on comparable sales. The 1-month decline of 4.84% captures the residual post-earnings weakness, while the identical 1-day and 5-day gains of 2.38% indicate that the entire five-day advance occurred in the most recent session, suggesting the stock was range-bound immediately prior. The $104.87 level (1 September) represents the most recent identifiable support, formed in the immediate aftermath of the earnings sell-off; the implied YTD-flat level near $111.4 represents the nearest overhead resistance/reference point to reclaim the 2026 opening price.

Investment Thesis

The Walmart investment case rests on five pillars: (1) scale-driven omnichannel dominance in U.S. retail, (2) a rapidly monetizing advertising and data business (Walmart Connect), (3) international growth optionality, particularly in China, (4) diversification into adjacent services (delivery, fintech-like logistics, fashion private label), and (5) margin support from tariff refunds and operating leverage. Company-specific risks include pharmacy margin erosion from Medicare drug-price regulation and decelerating core U.S. comparable sales, while market-wide factors include consumer spending sensitivity to fuel/energy costs and broader macro caution among middle-income shoppers.

Thesis Status

The thesis remains structurally intact but is under near-term pressure. Q2 FY2027 results confirmed revenue growth (+6% YoY to $186.1–187.9 billion) but also profitability compression, with net income down 9% and diluted EPS down 9% to $0.80, driven by pharmacy headwinds and rising fuel costs. Management's decision to raise full-year sales guidance to 4–5% (from 3.5–4.5%) despite the comp-sales miss signals confidence in underlying demand, and the post-earnings rebound (+4.6% off the September low) suggests the market has partially re-rated the stock after the initial overreaction. However, Q3 EPS guidance of $0.62–0.64 below the $0.68 consensus keeps near-term earnings risk elevated, and the thesis's validation now depends on whether advertising, e-commerce, and international growth can offset continued pharmacy and margin pressure.

Key Drivers

• Q2 FY2027 comparable sales growth of 2.6%, the slowest in six years, missed the 3.8% consensus and triggered a 7–8% single-day decline on 20 August (Reuters, CNBC).
• Pharmacy headwinds from Medicare drug-price negotiations are expected to persist into 2026, per CFO John David Rainey (Forbes).
• Walmart China delivered 20.7% sales growth, with over 50% of revenue now online, reinforcing the international growth pillar (Fortune).
• Walmart Connect advertising revenue reached $6.4 billion, tripling over four years at ~70% margins, positioning Walmart as a major media platform (Morningstar).
• Expansion into restaurant delivery via Dunkin' and Subway partnerships leverages Walmart's logistics footprint to compete with DoorDash/Uber Eats (CNBC).
• Tariff refunds of $2.9 billion supported 96bps gross margin expansion, partially offsetting an expected $2 billion fuel cost headwind (Morningstar).
• Walmart settled the DOJ opioid lawsuit, removing a legal overhang, with shares rising 0.5% on the news (CNBC).

Technical Analysis

WMT is in a technical recovery phase following the sharp post-earnings decline. The stock has stabilized above the $104.87 support level established on 1 September, with the most recent session contributing the full 2.38% five-day gain, indicating a potential acceleration in near-term momentum. The stock remains below its YTD reference price (~$111.4, implied by the -1.54% YTD figure) and well below the six-month high (~$126.5, implied by the -13.30% six-month change), both of which represent resistance zones to monitor. Sustained trading above $110 would support a continuation toward the YTD breakeven level; failure to hold above the $105–107 range would suggest renewed downside risk toward the September low.

Bull Case

• Walmart Connect advertising business generates $6.4 billion in revenue at ~70% margins and has tripled in four years, offering a high-margin growth vector independent of core retail (Morningstar).
• Walmart China posted 20.7% sales growth with over 50% online penetration, demonstrating successful omnichannel execution and international growth optionality (Fortune).
• Management raised full-year sales growth guidance to 4-5% and adjusted EPS guidance to $2.80-$2.87 despite the comp-sales miss, signaling underlying confidence (Reuters, Axios).
• E-commerce sales grew 24% with store-fulfilled deliveries up over 40% and fast delivery (under 30 minutes) up 48%, supported by new restaurant delivery partnerships with Dunkin' and Subway (WSJ, CNBC).
• Expected $2.9 billion in tariff refunds drove 96bps of gross margin expansion, funding continued price investment across 11,000+ items to defend market share (Morningstar, WSJ).

Bear Case

• Net income declined 9% YoY to $6.37 billion and diluted EPS fell 9% to $0.80 despite 6% revenue growth, indicating material margin compression (SEC EDGAR 10-Q).
• U.S. comparable sales growth of 2.6% marked the slowest pace in six years and missed consensus estimates of 3.5-3.8%, described by one analyst as "one of the biggest misses in years" (CNBC, Fortune).
• Pharmacy sales face a persistent 0.8% headwind from Medicare drug-price negotiations, an issue management expects to continue into 2026 (Forbes).
• Q3 FY2027 EPS guidance of $0.62-$0.64 fell below the $0.68 analyst consensus, and average transaction value growth slowed to 1.1% from 3.1% YoY, signaling consumer pullback (Reuters).
• Walmart anticipates $2 billion in incremental fuel-related cost headwinds in 2026, which could further pressure margins even as tariff refunds provide a partial offset (Forbes).